Medical Xpress·5 min read·hard
Drug nearly doubles survival in advanced pancreatic cancer-how daraxonrasib overcame an 'undruggable' disease
✦AI Summary
A new drug, daraxonrasib, has shown promise in treating advanced pancreatic cancer by targeting the KRAS protein mutation. This development is significant because pancreatic cancer has historically been considered 'undruggable' and has very low survival rates.
Why it matters
This breakthrough offers a potential life-extending treatment for one of the deadliest forms of cancer, representing a major shift in oncology research.
edited by Lisa Lock , reviewed by Andrew Zinin
healthscience
Political Bias
Center
LeftLean LCenterLean RRight
Confidence: 95%
The article is a scientific report focusing on medical advancements and clinical trial outcomes.
✦
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in